25603 Improvement in scalp psoriasis and quality of life with apremilast in patients with moderate to severe scalp psoriasis regardless of prior systemic treatment: Results from the phase 3, randomized STYLE study
Wang Y, Gold LS, Lebwohl M, Strober B, Zhang Z, and Van Voorhees A. 25603 Improvement in scalp psoriasis and quality of life with apremilast in patients with moderate to severe scalp psoriasis regardless of prior systemic treatment: Results from the phase 3, randomized STYLE study. J Am Acad Dermatol 2021; 85(3):AB63.
J Am Acad Dermatol
Background: Apremilast 30 mg BID (APR) provided greater improvements in scalp psoriasis and quality of life vs placebo (PBO) in a phase 3 study in patients with moderate-to-severe plaque psoriasis of the scalp. We present subgroup analyses based on systemic treatment history.
Methods: Patients with moderate-to-severe scalp psoriasis (Scalp Physician’s Global Assessment ≥3, psoriasis-involved scalp surface area [SSA] ≥20%) and moderate-to-severe plaque psoriasis with inadequate response/intolerance to ≥1 topical therapy were randomized to double-blind APR or PBO for 16 weeks. SSA (last observation carried forward) and Dermatology Life Quality Index (DLQI; multiple imputation) changes were analyzed by ANCOVA in intent-to-treat (ITT) population subgroups based on prior systemic treatment.
Results: 303 patients were randomized to APR (ITT: 201; prior systemic: 99; no prior systemic: 102) or PBO (ITT: 102; prior systemic: 49; no prior systemic: 53). Mean baseline assessments were similar with APR vs PBO for SSA involvement and DLQI: SSA - Prior systemic: 61.9% vs 56.2% - No prior systemic: 61.8% vs 60.0% DLQI - Prior systemic: 13.3 vs 12.8 - No prior systemic: 12.0 vs 12.5 At Week 16, APR patients achieved greater improvements vs PBO (least-squares mean differences): SSA - Prior systemic: −27.3%, P =.0003 - No prior systemic: −33.6%, P ˂.0001 DLQI - Prior systemic: −3.4, P =.0003 - No prior systemic: −2.6, P =.0016.
Conclusions: APR demonstrated a consistent treatment effect vs PBO in moderate-to-severe scalp psoriasis patients with and without a history of prior systemic treatment.